Across TCGA pan-cancer cohorts, TRABD2A RNA is linked to patient survival in 20 of 34 cancer types, making it the most broadly survival-associated TRABD2A data layer compared with 7 for mutation status.
The strongest signal is observed in mesothelioma (MESO), where higher TRABD2A RNA is associated with worse overall survival. In most high-consensus cancer types, elevated TRABD2A expression acts as an unfavorable survival marker, although some lineages such as THCA and UVM show a favorable association.
MESO, THCA, and UVM are the cancer types where TRABD2A RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.